This MedLibrary.org supplementary page on Paliperidone is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Paliperidone
|
|
| Systematic (IUPAC) name | |
| 3-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-7- hydroxy-4-methyl-1,5-diazabicyclo[4.4.0]deca-3,5-dien-2-one |
|
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C23H27FN4O3 |
| Mol. mass | 426.484 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 28% |
| Metabolism | ? |
| Half life | 23 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
℞ Prescription only |
| Routes | oral- extended release |
Paliperidone (sold as INVEGA) is an atypical antipsychotic developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone, i.e. risperidone with an extra hydroxyl group). It is indicated in the treatment of schizophrenia, as well as manic and mixed episodes occurring in conjunction with Bipolar I Disorder, and depression.
Contents |
Pharmacology
While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways; therapeutic effect may be due to a combination of D2 and 5-HT2A receptor antagonism. Paliperidone also has antagonist effect at α1 and α2 adrenergic receptors and at H1 histamine receptors.[1]
Paliperidone (as Invega) was approved by the FDA for the treatment of schizophrenia on December 20, 2006. This agent will initially be marketed for the treatment of schizophrenia and then for bipolar mania. Clinical trials of paliperidone for the treatment of schizoaffective disorder are also planned. It may also be used off-label for other conditions. The drug significantly reduces side-effects present in other anti-psychotic drugs formerly used to treat both schizophrenia as well as bipolar disorder[citation needed]. Like risperidone, its possible use in autism and Asperger's syndrome may be studied.
See also
References
- ^ "Prescribing Reference: New Product Releases - INVEGA". Retrieved on 2008-05-25.
External links
|
|||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 26 June 2008, at 13:40.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Paliperidone".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.